Neil Lindsay Berkley Sells 37,261 Shares of Alector (NASDAQ:ALEC) Stock

Alector, Inc. (NASDAQ:ALEC) CFO Neil Lindsay Berkley sold 37,261 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $41,732.32. Following the sale, the chief financial officer directly owned 374,309 shares of the company’s stock, valued at $419,226.08. This represents a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alector Price Performance

Alector stock opened at $1.21 on Friday. The business’s fifty day moving average is $1.97 and its two-hundred day moving average is $1.94. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.76 and a current ratio of 3.76. The firm has a market cap of $132.07 million, a P/E ratio of -1.13 and a beta of 0.67. Alector, Inc. has a 52 week low of $0.87 and a 52 week high of $3.40.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%.The business had revenue of $3.26 million during the quarter, compared to analysts’ expectations of $3.49 million. Equities research analysts forecast that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alector

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC raised its position in shares of Alector by 39.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company’s stock valued at $1,768,000 after acquiring an additional 410,205 shares during the period. Ieq Capital LLC bought a new stake in Alector in the first quarter valued at approximately $99,000. Jacobs Levy Equity Management Inc. raised its holdings in Alector by 25.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company’s stock worth $1,641,000 after purchasing an additional 274,341 shares during the period. Invesco Ltd. boosted its position in shares of Alector by 209.6% during the first quarter. Invesco Ltd. now owns 148,576 shares of the company’s stock worth $183,000 after purchasing an additional 100,591 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Alector by 49.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 52,095 shares of the company’s stock worth $73,000 after purchasing an additional 17,170 shares in the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. William Blair lowered shares of Alector from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 22nd. TD Cowen cut Alector from a “buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Cowen lowered Alector to a “hold” rating in a research note on Wednesday, October 22nd. HC Wainwright decreased their price target on Alector from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Finally, Mizuho set a $1.50 target price on shares of Alector and gave the company a “neutral” rating in a research report on Wednesday, October 22nd. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $3.40.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.